Mark Frohlich – Biography
Last update: December 2, 2025Executive profile
Mark was Executive Vice President of Portfolio Strategy at Juno Therapeutics, and Executive Vice President, Research and Development and Chief Medical Officer at Dendreon. Mark Frohlich joined Indapta Therapeutics in 2025.
Mark Frohlich is currentlyChief Executive Officer at Indapta Therapeutics - View - Indapta Therapeutics org chart
Director at Rigel Pharmaceuticals - View - Rigel Pharmaceuticals org chart
Create your alert
to follow the career of Mark Frohlich.
Education
Mark Frohlich has a Bachelor of Science in Economics and Electrical Engineering from Yale University in 1984 and a Doctor of Medicine from Harvard Medical School in 1990.
They have also studied at Yale University :
Find more alumni from Yale University
They have also studied at Harvard Medical School :
Find more alumni from Harvard Medical School
More about Mark Frohlich
Selected links
Do you need to know more about Mark Frohlich? More results.
Participate
Social media
- Mark Frohlich on Google News, X (Twitter), LinkedIn, YouTube
- View the pictures of Mark Frohlich
The colleagues of Mark Frohlich
Company Colleagues
- At Indapta Therapeutics, Mark Frohlich has 9 colleagues including Fabio Pucci (Director), Lori Hu (Director)…
- At Rigel Pharmaceuticals, Mark Frohlich has 26 colleagues including Raul Rodriguez (CEO), Walter Moos (Director)…
Industry Colleagues
- In the Biotechnology industry, Mark Frohlich has 35,756 colleagues in 2,406 companies located in 42 countries. 16,856 executive movements have been recorded in the last 12 months. Learn more about Biotechnology.
Report an error
Update the org chart details of Mark Frohlich.
Get in Touch
Here are a few tips for establishing great contacts.
and ask for Mark Frohlich.
